TY  - JOUR
A1  - Lötters, Stefan
A1  - Jung, Alisha
A1  - Weifenbach, Niels
T1  - COVID-19 infection in CVID patients: What we know so far
T2  - Immunity, Inflammation and Disease
N2  - Introduction:In patients with common variable immunodeficiency (CVID),immunological response is compromised. Knowledge about COVID‐19 in CVIDpatients is sparse. We, here, synthesize current research addressing the level ofthreat COVID‐19posestoCVIDpatientsandthebest‐known treatments.

Method:Review of 14 publications.

Results:The number of CVID patients with moderate to severe (~29%) andcritical infection courses (~10%), and the number of fatal cases (~13%), areincreased compared to the general picture of COVID‐19 infection. However,this might be an overestimate. Systematic cohort‐wide studies are lacking, andasymptomatic or mild cases among CVID patients occur that can easily remainunnoticed. Regular immunoglobulin replacement therapy was administered inalmost all patients, potentially explaining why the numbers of critical and fatalcases were not higher. In addition, the application of convalescent plasma wasdemonstrated to have positive effects.

Conclusions:COVID‐19 poses an elevated threat to CVID patients. However,only systematic studies can provide robust information on the extent of thisthreat. Regular immunoglobulin replacement therapy is beneficial to combatCOVID‐19 in CVID patients, and best treatment after infection includes theuse of convalescent plasma in addition to common medication.
KW  - common variable immunodeficiency
KW  - convalescent plasma
KW  - immunoglobulin replacement
KW  - SARS‐CoV‐2
KW  - SARS-CoV-2
KW  - Immundefekt
KW  - Plasmaersatz
KW  - Immunglobulintherapie
Y1  - 2021
UR  - https://ubt.opus.hbz-nrw.de/frontdoor/index/index/docId/1811
UR  - https://nbn-resolving.org/urn:nbn:de:hbz:385-1-18114
VL  - 2021
IS  - Band 9, Heft 3
SP  - 632
EP  - 634
PB  - Wiley
CY  - Hoboken
ER  -